# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Misonix (NASDAQ:MSON) reported $19.68 million in sales this quarter. This is a 43.55 percent increase over sales of $13.71 mill...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitti...
BTIG analyst Ryan Zimmerman downgrades Misonix (NASDAQ:MSON) from Buy to Neutral.
Gainers
Gainers
Craig-Hallum downgrades Misonix (NASDAQ:MSON) from Buy to Hold and raises the price target from $23 to $28.
On Friday morning, 154 companies achieved new highs for the year.